Harpoon Therapeutics, Inc. (HARP)
Stock Price:
$16.59 USD
-0.90 (-5.15%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
414.72M |
| Revenue (ttm) |
8.01M |
| Net Income (ttm) |
-54.55M |
| Shares Out |
25.00M |
| EPS (ttm) |
-2.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$16.59 |
| Previous Close |
$17.49 |
| Change ($) |
-0.90 |
| Change (%) |
-5.15% |
| Day's Open |
17.50 |
| Day's Range |
16.25 - 17.50 |
| Day's Volume |
121,408 |
| 52-Week Range |
10.27 - 25.02 |
More Stats
| Market Cap |
414.72M |
| Enterprise Value |
306.28M |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.00M |
| Float |
8.33M |
| EPS (basic) |
-2.26 |
| EPS (diluted) |
-2.25 |
| FCF / Share |
-0.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
220,830 |
| Short Ratio |
0.73 |
| Short % of Float |
1.69% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
51.77 |
| PB Ratio |
5.43 |
| Revenue |
8.01M |
| Operating Income |
-57.23M |
| Net Income |
-54.55M |
| Free Cash Flow |
-11.43M |
| Net Cash |
108.44M |
| Net Cash / Share |
4.34 |
| Gross Margin |
-447.07% |
| Operating Margin |
-714.38% |
| Profit Margin |
-680.90% |
| FCF Margin |
-142.70% |
| ROA |
-21.70% |
| ROE |
-50.30% |
| ROIC |
-56.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
8 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$30.89*
(86.20% upside)
Low
24.0
Current: 16.59
High
36.0
Target: 30.89
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 5.78 | 4.75 | 0.71 | - |
| Revenue Growth | 21.62% | 570.9% | - | - |
| Gross Profit | 5.78 | 4.75 | 0.71 | - |
| Operating Income | -58.25 | -27.76 | -16.62 | -11.15 |
| Net Income | -55.57 | -27.37 | -16.83 | -11.41 |
| Shares Outstanding | 21.75 | 1.07 | 0.89 | 0.53 |
| Earnings Per Share | -2.56 | -25.65 | -18.81 | -21.61 |
| Operating Cash Flow | -2.89 | -27.13 | 1.71 | -10.79 |
| Capital Expenditures | -3.52 | -0.66 | -2.28 | -0.55 |
| Free Cash Flow | -6.41 | -27.79 | -0.56 | -11.35 |
| Cash & Equivalents | 148 | 89.49 | 29.42 | 7.74 |
| Total Debt | 14.94 | - | - | 2.31 |
| Net Cash / Debt | 133 | 89.49 | 29.42 | 5.42 |
| Assets | 177 | 103 | 31.87 | 8.38 |
| Liabilities | 82.38 | 26.48 | 18.97 | 3.90 |
| Book Value | 94.22 | -53.48 | -26.94 | -10.44 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Harpoon Therapeutics, Inc. |
| Country |
United States |
| Employees |
67 |
| CEO |
Gerald McMahon |
Stock Information
| Ticker Symbol |
HARP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: HARP |
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.